Evaluation of the Benefit of Ropeginterferon Treatment in Patients with Polycythemia Vera
Results: Twenty-three patients (15 men and 8 women) with a median age of 57 years were enrolled, with 87.5% having the JAK617F mutation. Six patients had a history of thrombosis. Besremi was used as a first-line treatment in 11 patients and as a second-line treatment in 12 patients after Hydroxyurea...
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Romanian Society of Hematology
2025-03-01
|
| Serie: | Documenta Haematologica |
| Soggetti: | |
| Accesso online: | https://www.dhrrh.ro/wp-content/uploads/2025/03/DHRRH-2025-1-art5.pdf |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|